Duell J - Search Results

1

Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.

Topp MS, Duell J, Guijarro AMA, Odin M, Nielsen T, Rajeswaran A, Wenger M, Zundel C, Bogucka-Fedorczuk A, Wrobel T. Topp MS, et al. Among authors: duell j. Haematologica. 2020 May;105(5):e256-e260. doi: 10.3324/haematol.2019.233189. Epub 2020 Feb 6. Haematologica. 2020. PMID: 32029506 Free PMC article. No abstract available.

2

Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.

Stuehler C, Mielke S, Chatterjee M, Duell J, Lurati S, Rueckert F, Einsele H, Bargou RC, Topp MS. Stuehler C, et al. Among authors: duell j. Blood. 2009 Sep 24;114(13):2829-36. doi: 10.1182/blood-2009-06-224600. Epub 2009 Aug 5. Blood. 2009. PMID: 19657113 Free article.

3

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.

Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, Haralambieva E, Maeder U, Einsele H, Knop S. Rasche L, et al. Among authors: duell j. Ann Hematol. 2012 Jul;91(7):1031-7. doi: 10.1007/s00277-012-1414-5. Ann Hematol. 2012. PMID: 22286070

4

The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.

Rasche L, Duell J, Morgner C, Chatterjee M, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S. Rasche L, et al. Among authors: duell j. PLoS One. 2013 May 7;8(5):e63414. doi: 10.1371/journal.pone.0063414. Print 2013. PLoS One. 2013. PMID: 23667612 Free PMC article.

5

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S. Rasche L, et al. Among authors: duell j. Haematologica. 2015 Mar;100(3):377-84. doi: 10.3324/haematol.2014.117945. Epub 2015 Jan 30. Haematologica. 2015. PMID: 25637055 Free PMC article. Clinical Trial.

6

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.

Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, Topp MS. Duell J, et al. Leukemia. 2017 Oct;31(10):2181-2190. doi: 10.1038/leu.2017.41. Epub 2017 Jan 25. Leukemia. 2017. PMID: 28119525 Free PMC article.

7

Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M. Nagel I, et al. Among authors: duell j. Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21. Blood. 2017. PMID: 28827408 Free PMC article. Clinical Trial.

8

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.

Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT Jr, Trippett T, Duell J, Bargou RC, Holland C, Benjamin JE, Klinger M, Litzow MR. Topp MS, et al. Among authors: duell j. Leukemia. 2018 Feb;32(2):562-565. doi: 10.1038/leu.2017.306. Epub 2017 Oct 9. Leukemia. 2018. PMID: 28990581 Free PMC article. No abstract available.

9

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.

Duell J, Lukic DS, Karg M, Reusch U, Koch J, Zhukovsky EA, Rajkovic E, Treder M, Rasche L, Eisele F, Einsele H, Topp MS. Duell J, et al. J Immunother. 2019 Jun;42(5):180-188. doi: 10.1097/CJI.0000000000000267. J Immunother. 2019. PMID: 31090657

10

The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.

Einsele H, Rasche L, Topp MS, Martin Kortüm K, Duell J. Einsele H, et al. Among authors: duell j. Bone Marrow Transplant. 2019 Aug;54(Suppl 2):721-726. doi: 10.1038/s41409-019-0596-z. Bone Marrow Transplant. 2019. PMID: 31431702

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page